Drugs · acquisition-cost intelligence
fenofibrate
· ingredient fenofibrate· FENOFIBRATE 120 mg/1; FENOFIBRATE 40 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$5.82
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-06-03
Same-ingredient options by acquisition cost
Other fenofibrate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Fenofibrate | $0.08557 | −$5.73 |
| fenofibrate | $0.11260 | −$5.70 |
| Tricor | $0.11985 | −$5.70 |
| fenofibrate | $0.12388 | −$5.69 |
| Fenofibrate | $0.16790 | −$5.65 |
| FENOFIBRIC ACID DELAYED-RELEASE | $0.25649 | −$5.56 |
| ANTARA | $0.66591 | −$5.15 |
Medicare Part D coverage · CY2026
On 7 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 14% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.